Targeted Drug Delivery Partnering 2010-2015 report provides understanding and access to the targeted drug delivery partnering deals and agreements entered into by the world’s leading healthcare companies.
- Trends in targeted drug delivery partnering deals
- Top targeted drug delivery deals by value
- Deals listed by company A-Z, deal type, stage of development, therapy type
Targeted Drug Delivery Partnering 2010-2015 provides understanding and access to the targeted drug delivery partnering deals and agreements entered into by the world’s leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter targeted drug delivery partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 150 links to online copies of actual targeted drug delivery deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of targeted drug delivery dealmaking and business activities.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in targeted drug delivery dealmaking since 2010
Chapter 3 is the most popular chapter that includes details of average headline, upfront, milestone and royalty terms.
Chapter 4 provides a review of the leading targeted drug delivery deals since 2010. Deals are listed by headline value, most active of all biopharma companies and signed by big pharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides a comprehensive directory of targeted drug delivery partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and therapy type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in targeted drug delivery partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about targeted drug delivery partnering in the research, development and commercialization of drug delivery technologies and products.
Targeted Drug Delivery Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to targeted drug delivery trends and structure of deals entered into by leading companies worldwide.
This data driven report includes:
- Trends in targeted drug delivery dealmaking in the biopharma industry since 2010
- Access to summary headline, upfront, milestone and royalty data
- Access to over 150 targeted drug delivery actual deal records
- The leading targeted deals by value since 2010
In Targeted Drug Delivery Partnering 2010-2015, the available deals are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Company A-Z
- Industry sector
- Stage of development at signing
- Deal component type
- Therapy type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Table of Content
Chapter 1 – Introduction
Chapter 2 – Trends in targeted drug delivery dealmaking
2.2. Targeted drug delivery partnering over the years
2.3. Big pharma targeted drug delivery dealmaking activity
2.4. Targeted drug delivery partnering by industry type
2.5. Targeted drug delivery partnering by deal type
2.6. Targeted drug delivery partnering by disease type
Chapter 3 –Average financial deal terms for targeted drug delivery partnering
3.1 Targeted drug delivery deals by headline values
3.2 Targeted drug delivery upfront payments
3.3 Targeted drug delivery milestone payments
3.4 Targeted drug delivery royalty rates
Chapter 4 – Leading targeted drug delivery deals
4.2. Most active in targeted drug delivery partnering
4.3. Top targeted drug delivery deals by value
Chapter 5 – Targeted drug delivery partnering dealmaking directory
5.2. Company A-Z
5.3. By deal type
5.4. By stage of development
5.5. By industry sector
5.6. By therapy area
About Wildwood Ventures
Recent report titles from CurrentPartnering
Order Form – Upgrades to subscription access products
List of Chart
Figure 1: Targeted drug delivery partnering since 2010
Figure 2: Big pharma – top 50 – Targeted drug delivery deals 2010 to 2015
Figure 3: Big pharma targeted drug delivery deal frequency – 2010 to 2015
Figure 4: Targeted drug delivery partnering by industry sector since 2010
Figure 5: Targeted drug delivery partnering by deal type since 2010
Figure 6: Targeted drug delivery partnering by disease type since 2010
Figure 7: Targeted drug delivery deals with a headline value
Figure 8: Targeted drug delivery deals with an upfront value
Figure 9: Targeted drug delivery deals with a milestone value
Figure 10: Targeted drug delivery deals with a royalty rate value
Figure 11: Active targeted drug delivery dealmaking activity– 2010 to 2015
Figure 12: Top targeted drug delivery deals by value since 2010
Make an enquiry before buying this Report
Please fill the enquiry form below.